These results provide compelling preclinical evidence for application of copanlisib in advanced MCC with aberrant PI3K activation for which immunotherapy is insufficient, or patients who are unsuitable for immunotherapy. This evidence concerns the gene PIK3CA and Merkel cell skin cancer.